Compare Novartis AG (NVS) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Standard Lithium Ltd — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Standard Lithium Ltd trades at $2.45 (market cap $624.94M). The key difference: Novartis AG is far larger — about 477.1× Standard Lithium Ltd's market cap, and Novartis AG pays a 3.02% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| NVS | SLI | |
|---|---|---|
Market Cap | $298.18B | $624.94M |
Sector | Health | Basic Materials |
52-Week High | $168.62 | $5.65 |
52-Week Low | $119.31 | $1.93 |
Enterprise Value | $339.50B | $484.14M |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Standard Lithium (SLI) trades at $2.37, up 4.41% with a bullish technical signal despite mixed earnings performance. The company maintains 100% analyst buy ratings and strong institutional interest, including Amundi's 64.9% stake increase. Recent developments show progress toward final investment decision for the South West Arkansas lithium project, supported by a $225M DOE grant and key construction contracts. Financials reflect development-stage challenges with negative profitability metrics but substantial financing activity.
Outlook remains constructive as SLI transitions toward production with major project de-risking, though execution risks and negative cash flows warrant monitoring. The stock presents growth potential in lithium sector expansion but faces operational and funding challenges during development phase. Current valuation at 1.72x book value reflects market optimism about project economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
